- INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS
-
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
- -
-
Page/Page column 40; 124
(2022/02/05)
-
- COMBINATION PRODUCT FOR THE TREATMENT OF CANCEROUS DISEASES
-
The present invention relates to a product for combination therapies useful for the treatment of cancer diseases. In particular, the invention relates to the combination of an anti-PD-Ll antibody and an MCT4 inhibitor of Formula (I). The therapeutic combination may be utilized for the use in treating a subject having a cancer disease that tests positive for PD-L1 and/or MCT4 expression.
- -
-
Page/Page column 168-169
(2021/12/31)
-
- DISUBSTITUTED ALKYNE DERIVATIVES
-
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
- -
-
Page/Page column 160-163
(2020/07/14)
-
- PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
-
The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated
- -
-
Paragraph 0105
(2020/10/21)
-
- BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS
-
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor
- -
-
Paragraph 1154-1155
(2019/05/15)
-
- INDOLIN-2-ONE DERIVATIVES
-
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein the substituents are defined in claim 1. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of s
- -
-
Page/Page column 50
(2017/06/15)
-
- Fused Pyrazoles as FGFR Inhibitors
-
The present invention relates to fused pyrazole derivatives, and pharmaceutical compositions including the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
- -
-
Paragraph 0391
(2014/06/25)
-
- ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS
-
The present invention provides isoindolinone and pyrrolopyridinone derivatives, as well as their compositions and methods of use, that inhibit the activity of the serine/threonine kinase, Akt, and are useful in the treatment of diseases related to the act
- -
-
-
- Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
-
The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
- -
-
Paragraph 0347
(2013/05/08)
-
- Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
-
The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
- -
-
Paragraph 0333; 0334
(2013/05/08)
-
- SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760
-
The present invention provides compounds of formula (I) in which, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
- -
-
-
- SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750
-
The present invention provides compounds of formula (I), in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
- -
-
Page/Page column 123
(2010/11/18)
-
- AZA-ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 613
-
Compounds of formula I: wherein R1, R2, R3,R4, R5, R6, R7, R8 and n are defined in the specification, methods for using said compounds, methods for making said compoun
- -
-
-